MAINZ, Germany, February 24, 2025 — (Nasdaq: BNTX, “BioNTech” or “the Company”) will release its fourth quarter and full year 2024 financial performance data on Monday, March 10, 2025. The company will also conduct a conference call and live webcast at 8:00 a.m. EDT (1:00 p.m. CET) on the same day for investors, analysts, and the public to discuss the results and provide a corporate update.
To join the live conference call via phone, please register through this . Upon registration, you will receive dial-in numbers and a PIN. Registering at least one day in advance is recommended. The presentation slides and webcast audio will be accessible via this .
Participants can also find the slides and conference call webcast on the “Events & Presentations” page within the Investor Relations section of the company’s website at . A webcast replay will be available shortly after the call and archived on the company’s website for 30 days.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global immunotherapy company focused on developing novel therapies for cancer and other serious diseases. BioNTech utilizes a variety of computational discovery and therapeutic drug platforms to rapidly develop new biopharmaceuticals. Its oncology pipeline includes personalized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, protein-based therapeutics like bispecific immune checkpoint modulators, targeted cancer antibodies, and antibody-drug conjugate (ADC) therapies, as well as small molecules. Leveraging its expertise in mRNA vaccine development and in-house manufacturing, BioNTech and its collaborators are researching and developing mRNA vaccine candidates for various infectious diseases alongside its oncology programs. BioNTech has partnerships with numerous global and specialized pharmaceutical companies, including DualityBio, Fosun Pharma, Genentech (a member of the Roche Group), Genevant, Genmab, MediLink, OncoC4, Pfizer, and Regeneron.
For further details, please visit .
CONTACTS
Investor Relations
Michael Horowicz
Media Relations
Jasmina Alatovic
“`